HER2 testing in gastric cancer: An update
HER2 testing in gastric cancer: An update
复制标题
DOI：
10.3748/wjg.v22.i19.4619
复制
发表时间：
2016-05-21
影响因子：
4.3
通讯作者：
Scapulatempo-Neto, Cristovam
中科院分区：
文献类型：
--
作者：
Abrahao-Machado, Lucas Faria;Scapulatempo-Neto, Cristovam
人表皮生长因子受体2（HER2）过度表达被认为是胃癌和胃食管癌中常见的分子异常。随着最近对晚期胃癌患者引入HER2分子靶向治疗，确定HER2状态对于选择可能从该治疗中获益的患者至关重要。本文提供了我们对胃癌和胃食管癌中HER2的最新认识，包括HER2的预后相关性，乳腺癌和胃癌中HER2蛋白表达解释的关键差异，检测方法和免疫组化评分系统。
Human epidermal growth factor receptor 2 (HER2) overexpression is increasingly recognized as a frequent molecular abnormality in gastric and gastroesophageal cancer. With the recent introduction of HER2 molecular targeted therapy for patients with advanced gastric cancer, determination of HER2 status is crucial in order to select patients who may benefit from this treatment. This paper provides an update on our knowledge of HER2 in gastric and gastroesophageal cancer, including the prognostic relevance of HER2, the key differences between HER2 protein expression interpretation in breast and gastric cancer, the detection methods and the immunohistochemistry scoring system.